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Sunday, February 16, 2014 101aIn order to investigate the molecular mechanism by which ligands control the
degree of activation of the metabotropic glutamate receptor (mGluR), a class C
G-protein Coupled Receptor (GPCR), we monitored the kinetics of the confor-
mational re-orientation that occurs within the extracellular ligand-binding
domain, and which has been shown mandatory for G-protein activation. Using
single molecule Fo¨rster Resonance Energy Transfer, we demonstrate that the
receptor continuously oscillates between a resting- and an active- state on a
sub-millisecond timescale, and that the role of ligands is exclusively to influ-
ence the transition rates between them, in agreement with the conformational
selection theory. In addition, this study reveals that the mechanism of action
of partial agonists is to finely tune the transition rates between these extreme
states, rather than stabilizing a static alternative conformation. Altogether,
these results represent a most-valuable contribution to the better understanding
of the activation mechanism of mGluRs, and possibly GPCRs in general, and
might contribute to facilitate the characterization of new potential drugs.
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Deregulation of the epidermal growth factor receptor (EGFR) signalling has
been correlated with the development of a variety of human carcinomas. Re-
ceptor dimerization and phosphorylation are amongst the earliest events in
signal transduction. Binding of EGF is thought to induce a conformational
change which unfolds an ectodomain loop required for dimerization. It may
also induce important allosteric changes in the cytoplasmic domain. Despite
these findings, ensemble-averaging methods could not resolve the details of re-
ceptor activation in situ. Here, we used two-color single-molecule imaging to
study the effect of ATP-competitive small molecule tyrosine kinase inhibitors
(TKI) and phosphatase-based manipulation of EGFR phosphorylation on live
cells. Ligand bound receptors were tracked on the plasma membrane with a so-
phisticated Bayesian segmentation tracking algorithm and the distribution of
dimer lifetimes was fitted to a single-exponential to extract dimer off-rates
(koff). Our data show that, pre-treatment with type I TKI, gefitinib (active
conformation binder) stabilizes the EGFR homodimer. Over-expression of
EGFR specific DEP-1 phosphatase was also found to have a stabilizing effect
on the homodimer. When a nonactivating anti-EGFR antibody, Snap-425 sin-
gle-chain variable fragment that competes for EGF binding was used as a
ligand, no significant difference in the koff of the dimer could be detected.
Conformational changes of the cytoplasmic part of the receptor upon gefitinib
pre-treatment were also confirmed by changes in Fluorescence Resonance En-
ergy Transfer (FRET) efficiency detected by ensemble FRET/FLIM (Fluores-
cence Lifetime Intensity Microscopy). These results provide direct evidence
that receptor phosphorylation is linked to dimer stability. The phosphorylated
and non-phosphorylated receptors exhibit different kinetics and cytoplasmic
conformations which may account for the heterogeneity in ligand-binding af-
finity observed through a concave-up Scatchard plot.
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Lateral diffusion enables efficient interactions between membrane proteins
leading to the transmission of chemical signals within and across the plasma
membrane. An open question in this context is how central cell surface recep-
tors are distributed over space and time and thereby influence the transmem-
brane signaling network. Here we study the mobility of a prototypical G
protein coupled receptor, the neurokinin 1 receptor (NK1R) during its
different phases of cellular signaling. The investigation of thousands of single
NK1R trajectories reveals a very characteristic mobility distribution pattern
with two major receptor populations, one showing high mobility and low
lateral restriction, the other low mobility and high restriction. The mobility
distribution pattern changes in a characteristic manner upon (i) agonist activa-
tion, (ii) receptor desensitization, (iii) receptor endocytosis, and (iv) receptor
recycling. The study uncovers the functional role of the heterogeneous spatio-
temporal distribution of individual GPCRs during the entire cellular signalling
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G-protein coupled receptors (GPCRs) are important cell signaling membrane
proteins that have been targeted by ~30-40% of marketed drugs for treating
many human diseases including cancer and heart failure. The X-ray crystal
structure of the M2 muscarinic receptor, a key GPCR that regulates human
heart rate and contractile forces of cardiomyocytes, was determined in an inac-
tive antagonist-bound state. Through accelerated molecular dynamics (aMD)
enhanced sampling simulation, we captured activation of the M2 receptor
that occurs on the millisecond timescales(1). The receptor activation is charac-
terized by large-scale structural rearrangements of the transmembrane helices
via an intermediate state. With activation-associated conformers of the M2 re-
ceptor revealed from aMD simulation, a fragment-based site mapping program
FTMAP is applied to explore the receptor surface. Seven allosteric sites are
identified with two distributed in the solvent-exposed extracellular and intracel-
lular mouth regions and five in the lipid-exposed pockets formed by transmem-
brane helices of the receptor(2). Virtual screening is then performed to select
small-molecule drugs that bind these allosteric sites with differential affinity
and thus stabilize the receptor in the corresponding conformational states. In
contrast to highly conserved residues in the orthosteric site where endogenous
ligands bind, residues in the allosteric sites exhibit large diversity across
different GPCR subtypes. Therefore, ligands that bind GPCR allosteric sites
are able to provide potential receptor-selective therapeutics.
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The mechanism of signaling via G protein-coupled receptors (GPCRs) remains
unresolved, and two questions have been the focus of much attention and
debate: namely, the oligomeric status of the receptor, and the nature of its inter-
action with the G protein. Here, we examine those questions with the M2
muscarinic receptor using a combination of dual-color fluorescence spectros-
copy (dcFCS) and Fo¨rster resonance energy transfer (FRET). The unambiguous
identification of a complex afforded by cross-correlation in dcFCS allows
recruitment to be distinguished from conformational effects as the basis of
changes in FRET. Both FRET and dcFCS were measured using a spectrally
well-separated pair of fluorescent proteins, eGFP and mCherry (mCh), which
were fused at the N- or the C-termini of the receptor and at position 91 of
the ai1-subunit of Gi1. Insertion of the fluorophore in ai1 did not disrupt func-
tion, as measured by ligand-induced changes in the fluorescence of Trp 211 in
switch region II. Oligomers of the receptor (eGFP-M2 and mCh-M2) and of the
G protein (eGFP-ai1b1g2 and mCh-ai1b1g2) were identified at the membrane of
live CHO cells. In the absence of an agonist, there is neither FRET nor cross-
correlation between receptor and G protein (M2-mCh and eGFP-ai1b1g2). Acti-
vation of the receptor by carbachol leads to a rapid increase in FRET and the
appearance of cross-correlation, which suggests that G proteins bind only to
activated receptors. Cross-correlation also revealed oligomers of the G protein
(eGFP-ai1b1g2 and mCh-ai1b1g2) in solution which persisted after the addition
of AlF4
. Taken together, our data suggest that an agonist promotes the tran-
sient interaction of an oligomer of receptors with an oligomer of heterotrimeric
G proteins.
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The Ga subunit of heterotirmeric G Proteins is responsible for regulating intra-
cellular signals through guanine nucleotide binding and release, the catalytic
rate limiting step. Recent studies have shown interactions of Ga with Guanine
102a Sunday, February 16, 2014nucleotide Exchange Factors (GEFs), including non-receptor-like GEFs, cause
dynamic structural changes which facilitate substrate release. Although
receptor-G Protein interactions are well known a lack of understanding of
non-receptor-G protein interactions still exists, namely Ga interactions with
the non-receptor GEF Ric-8A. A 10-to-100 fold decrease in nucleotide ex-
change rate for Ric-8A compared to receptors has been shown, which begs
the question: What is the cause for the decrease between receptor and non-
receptor GEF activity? To answer this, the dynamic and structural interactions
of Ga-Ric-8A have been probed by fluorescence anisotropy and single-
molecule Fo¨rster Resonance Energy Transfer (smFRET). Conformational
changes in the ms times-scale of inter and intra-domain states and increase
segmental motions of the switch (I-III) regions seem to play a role in substrate
release.
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The epidermal growth factor receptor (EGFR) is a member of the ErbB family
of receptor tyrosine kinases which play an important role in a number of phys-
iological responses and have also been identified as a common signaling
component in several cancer types. Physiological signaling is initiated by
ligand binding which stabilizes EGFR dimers, resulting in auto-
phosphorylation of the intracellular kinase domain. Mutation of EGFR is asso-
ciated with tumor progression due to constitutive activity resulting from several
known kinase domain variants. Our previous work has shown that ligand-
induced dimerization of wild type EGFR results in decreased receptor mobility,
and that this reduction in mobility is dependent on kinase activity. Therefore,
we wondered whether ligand-independent activity of EGFR mutants correlates
with differences in receptor mobility or dimerization kinetics.
Here, we employ multi-color, single particle tracking (SPT) of quantum dots to
visualize and quantify the dynamics and interactions of individual receptors
within the membrane. Using a novel, high-speed hyperspectral microscope,
we are able to track up to eight spectrally distinct quantum dots for visualiza-
tion and quantification of receptor interactions. From this data, we quantify re-
ceptor dimerization kinetics using a Hidden Markov Model. We find that
unliganded EGFR mutants exhibit a reduced mobility and longer dimer life-
times when compared to wild type. These results are consistent with constitu-
tive activity of the EGFR mutants and suggest that the active kinase domain
facilitates dimer formation in the absence of ligand. Moreover, we test the ef-
fects of clinical tyrosine kinase inhibitors on the single molecule behavior of
EGFR mutants. We further examined the mobility and clustering of EGFR
within the cellular actin cytoskeleton by hyperspectral tracking over GFP-
actin, as well as two-color super-resolution microscopy.
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BACKGROUND AND PURPOSE. Insulin stimulates the transport of glucose
in target tissues by triggering the translocation of glucose transporter 4 (GLUT4)
to the plasma membrane. Resistance to insulin, the major abnormality in type 2
diabetes, results in a decreased GLUT4 translocation efficiency, leading to hy-
perglycemia. Thus, special attention is drawn on the search for compounds,
termed insulin mimetics, which are able to enhance this translocation process
in the absence of insulin.
EXPERIMENTAL APPROACH. In the present work Total Internal Reflection
Fluorescence (TIRF) microcopy was applied to quantify GLUT4 translocation
in highly insulin sensitive CHO-K1 cells expressing a GLUT4-myc-GFP fusion
protein. Customized software was developed to further increase the throughput
capability.
KEYRESULTS.Using our approachwe proved theGLUT4 translocation inhib-
itory properties of selected substances in live and fixed cells. In addition,we vali-
dated the efficacy of known GLUT4 translocation inducers and characterized
newsubstances,mainly phytochemicals,with potential insulinmimetic function.CONCLUSIONS AND IMPLICATIONS. Taken together, TIRF microscopy
proved to be a superior tool for the quantification of GLUT4 translocation
and the search for insulin mimetic drugs.
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The human cannabinoid receptor, CB1, a G protein-coupled receptor (GPCR),
contains a somewhat long (~110 a.a.) amino terminus. We explored a potential
role for the CB1 N-terminus in modulating ligand binding to the receptor.
Although the majority of the CB1 N-terminus is not necessary for high-
affinity ligand binding, previous studies have found that mutations introduced
into a conserved membrane proximal region (MPR) do impair the receptors
ability to bind ligand. Moreover, the highly conserved MPR (~ residues 90-
110) contains two invariant cysteine residues that are conserved in all CB1 re-
ceptors. Our data suggest these two cysteines (C98 and C107) form a disulfide
in human CB1, and this C98-C107 disulfide is more accessible to reducing
agents than the disulfide in extracellular loop 2 (EL2). The presence of the
N-terminal C98-C107 disulfide appears to modulate ligand binding to the re-
ceptor in a way that can be quantitatively analyzed by an allosteric model.
The C98-C107 disulfide also alters the effects of CB1 allosteric ligands, Org
27569 and PSNCBAM-1. Our results provide new insights to how the N-termi-
nal MPR and EL2 act together to influence the high-affinity orthosteric ligand
binding site in CB1, and suggest the CB1 N-terminal MPR may be an area
through which allosteric modulators can act.
543-Pos Board B298
Monitoring Conformational Changes During Agonist Release from a
GPCR in Real Time: Transmembrane Helix 6 Resets as All-Trans Retinal
is Released from Rhodopsin
Chrisopher T. Schafer1, Jay M. Janz2, David L. Farrens1.
1OHSU, Portland, OR, USA, 2Pfizer, Cambridge, MA, USA.
The active metarhodopsin II (MII) conformation of rhodopsin loses activity
when it releases its agonist, all-trans retinal, and decays to the inactive apopro-
tein, opsin. Here, we studied how the conformational change and retinal release
are linked. In our experiments, we used tryptophan induced quenching of fluo-
rescence (TrIQ) to observe movement of transmembrane helix 6 (TM6) through
an attached fluorescent probe, while simultaneously measuring intrinsic trypto-
phan fluorescence to monitor retinal release. The data show TM6 moves from
its position in the active structure back into the helical bundle in opsin (indic-
ative of the inactive conformation) with a rate matching that of retinal exit; both
processes exhibit a t1/2 of ~15 minutes at 20C in 0.05% dodecyl maltoside at
pH 6.0. We further tested the correlation of these events in two ways. First, we
carried out an Arrhenius analysis and determined near identical activation en-
ergies for TM6 resetting and retinal release (~23 kcal/mol). Additionally, we
tested the effect of altering the rate of retinal release on the rate of the confor-
mational change. The release process was slowed by introducing a mutation to
the Schiff base counterion, E113Q. When retinal exit was slowed, the rate of
TM6 resetting decelerated to the same degree. Likewise, accelerating retinal
release by using hydroxylamine to hydrolyze the Schiff base linkage caused
a corresponding acceleration of the rate of TM6 movements. With these tools
in hand, we have begun investigating the dynamics and energetic of other
movements in the protein, with the goal of constructing a more comprehensive
model for receptor deactivation following light-activation, as well as testing
how mutations (such as retinitis pigmentosa), small molecules, and other pro-
teins can effect these events.
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With almost 1000 unique G Protein Coupled Receptors (GPCR’s) mapped in
the human genome, and an estimated 40% of current marketed drugs targeting
these proteins, there is little question that it worthwhile to develop newmethods
to more efficiently screen for small molecule agonists and antagonists. One
such group of GPCRs, the endothelin receptors, is home to one of the most
potent vasoconstrictors, the Endothelin A receptor (ETA) which is an excellent
target for selective antagonists for the treatment of pulmonary arterial hyperten-
sion. We have developed a method for screening selective antagonists which
target intracellular domains of ETA and ETB using a soluble template (to
mimic a region of the transmembrane domains of ETA and ETB) fused to
